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Background: Previously, investigators suggested that diagnostic substitution from 
other diagnoses, e.g., mental retardation (MR) and/or cerebral palsy (CP) to pervasive 
developmental disorder (PDD) is a driving factor behind increases in autism. This study 
evaluated potential diagnostic substitution among subjects diagnosed with PDD vs. MR 
or CP by examining birth characteristic overlap.
Methods: SAS® and StatsDirect software examined medical records for subjects within 
the Vaccine Safety Datalink database who were Health Maintenance Organization-
enrolled from birth until diagnosed with an International Classification of Disease, 9th 
revision (ICD-9) outcome of PDD (299.xx, n = 84), CP (343.xx, n = 300), or MR (317.xx, 
318.xx, or 319.xx, n = 51).
results: Subjects with PDD had significantly (p < 0.01) increased: male/female ratio 
(PDD = 5.5 vs. CP = 1.5 or MR = 1.3), mean age of initial diagnosis in years (PDD = 3.13 
vs. CP = 1.09 or MR = 1.62), mean gestational age in weeks at birth (PDD = 38.73 vs. 
CP = 36.20 or MR = 34.84), mean birth weight in grams (PDD = 3,368 vs. CP = 2,767 
or MR = 2,406), and mean Appearance-Pulse-Grimace-Activity-Respiration scores at 
1 min (PDD = 7.82 vs. CP = 6.37 or MR = 6.76) and 5 min (PDD = 8.77 vs. CP = 7.92 
or MR = 8.04), as compared to subjects diagnosed with CP or MR.
conclusion: This study suggests diagnostic substitution cannot fully explain increased 
PDD prevalence during the 1990s within the United States.
Keywords: asperger’s disorder, autism, cerebral palsy, diagnostic substitution, mental retardation, birth 
parameters
Abbreviations: ADDM, autism and developmental disabilities monitoring; APGAR, Appearance-Pulse-Grimace-Activity-
Respiration; ASD, autism spectrum disorder; CDC, Centers for Disease Control and Prevention; CP, cerebral palsy; DSM-IV, 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; HMOs, Health Maintenance Organizations; ICD-9, 
International Classification of Disease, 9th revision; IRB, Institutional Review Board; KPC, Kaiser Permanente Colorado; 
KPNC, Kaiser Permanente Northern California; KPNW, Kaiser Permanente North-West; MR, mental retardation; NIP: 
National Immunization Program; PDD, pervasive developmental disorder; US, United States; VSD, vaccine safety datalink.
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inTrODUcTiOn
Pervasive developmental disorders (PDD) are a diagnostic 
category characterized by delays in the development of socializa-
tion and communication skills (1). Although the typical onset 
of the symptoms associated with a PDD diagnosis occurs before 
a child is 3 years of age, parents may notice symptoms in early 
infancy (2). Problems with language; problems in relating to 
people, objects, and events; playing with toys and other objects 
in unusual ways; changes in routine or familiar surroundings 
being difficult; and body movements or behavior patterns that 
are repetitive are among the symptoms of a PDD diagnosis (3). 
Autism is the most common and best studied PDD. Asperger’s 
Syndrome, Childhood Disintegrative Disorder, and Rett’s 
Syndrome are other types of PDD diagnoses (3). Abilities, intel-
ligence, and behaviors vary widely among those diagnosed with a 
PDD. Among those with a PDD diagnosis, some have no spoken 
language, while limited phrases or conversation abilities are 
present in some, and relatively normal language development is 
present in others. Limited sociability and repetitive play is often 
evident. Atypical sensory responses to loud noises and lights are 
also common (3). Gastrointestinal disturbances (48%), incon-
tinence (57%), sleep problems (57%), eating disorders (94%), 
anxiety/fear (74%), behavioral problems (89%), and obsessive-
compulsive behaviors (92%) are commonly reported health, 
physical, and behavior symptoms among individuals diagnosed 
with a PDD (4).
It is apparent that PDD prevalence has increased 20- to 30-fold 
since studies conducted in the 1960s/1970s. In the 1960s/1970s, 
it was estimated that 1 in 2,500 children (0.04%) were diagnosed 
with a PDD (5), but by the 2000s prevalence estimates ranged 
from 1 to about 2% of all children without any correction for 
under ascertainment (6, 7).
As described previously by investigators (8), the Autism 
and Developmental Disabilities Monitoring (ADDM) Network 
is an active surveillance system providing estimates of the 
prevalence of autism spectrum disorder (ASD) among children 
8 years-old in specific areas of the United States (US) without 
any correction for under ascertainment. The earliest reports 
from the ADDM Network provided estimates of ASD preva-
lence among children for the 2000 and 2002 surveillance years. 
Data from 2000 and 2002 surveillance years indicated that the 
ASD prevalence was 6.7 per 1,000 in 2000 and 6.6 per 1,000 in 
2002, or approximately 1.0 in every 150 children (0.67%). It was 
reported in subsequent surveillance years that the estimated 
ASD prevalence rose to 8.0 per 1,000 in 2004 and 9.0 per 1,000 
in 2006, or about 1.0 in every 110 children in 2006 (0.9%). 
It was latter reported that for the 2008 surveillance year the 
prevalence of ASD increased to 11.3 per 1,000 children, or one 
in 88 children (1.13%). Finally, it was reported that for the 2010 
surveillance year the ASD prevalence rose to 14.7 per 1,000 
children, or one in 68 children (1.47%).
Since almost all of the PDD cases are ASD cases, there have 
been significant increases in estimated PDD prevalence in the 
US. Despite these increases in the size and the magnitude of 
ASD, some investigators have continued to suggest extrinsic 
factors such as changes in diagnostic practice account for much 
of the rise in ASD prevalence (9–11). Specifically, these inves-
tigators have suggested that diagnostic substitution from other 
diagnosis such as mental retardation (MR) and/or cerebral palsy 
(CP) to PDD is the driving factor behind the increases in PDD. 
As a result, a longitudinal hypothesis-testing epidemiological 
study was commenced to evaluate the potential for diagnostic 
substitution among children diagnosed by healthcare providers 
with a PDD in comparison to being diagnosed with MR or CP by 
evaluating automated medical records within the Vaccine Safety 
Datalink (VSD) database for the degree of overlap of various 
birth parameters associated with each of the diagnostic outcomes 
examined.
MaTerials anD MeThODs
The Institutional Review Board (IRB) of Kaiser Permanente 
North-West (KPNW), and the IRB of Kaiser Permanente 
Northern California (KPNC), as well as the US Centers for 
Disease Control and Prevention (CDC) approved the study 
protocol. The Research Data Center of the National Center for 
Health Statistics in Hyattsville, MD, US served as the secure 
location where the data for the present study was analyzed. CDC 
or Kaiser Permanente does not necessarily agree with the views 
expressed in this study.
As previously described, medical event information, specific 
vaccine history, and selected demographic information from 
the computerized databases of several Health Maintenance 
Organizations (HMOs) is linked in the VSD project (12–14). 
The National Immunization Program (NIP) created the VSD 
project in 1991. Children with non-missing dates of birth and 
gender, continuously enrolled within a VSD-participating HMO 
from birth, and had HMO birth files with no missing values were 
examined in this study.
Population at risk
SAS® software was utilized to examine a cohort of over one mil-
lion infants enrolled in the VSD project (updated through the 
end of 2000) from KPNW, Kaiser Permanente Colorado (KPC), 
and KPNC.
Determining subjects with Outcomes
The first instance of International Classification of Disease, 9th 
revision (ICD-9) healthcare provider diagnosed PDD (299.xx), 
CP (343.xx), or MR (317.xx or 318.xx or 319.xx) were identified 
from the outcome files (inpatient and outpatient diagnoses) 
in the VSD database. Given that a child might be diagnosed 
multiple times with the same diagnosis, only the child’s initial 
diagnosis was evaluated. It is also possible for subjects to be 
counted in more than one outcome category, since subjects with 
multiple different diagnoses were included in the present study. 
For the outcomes examined, Table 1 summarizes their overall 
demographics.
Determining Birth Demographics
Among the outcomes examined, the HMO birth file for 
each child was examined to determine each child’s ges-
tational age in weeks at birth, birth weight in grams, and 
TaBle 2 | a summary of the various types of birth measurements examined among the outcomes studied.
group examineda (icD-9 
code)
Mean gestational age at birth in 
weeks ± sD (95% ci)
Mean birth weight in 
grams ± sD (95% ci)
Mean aPgar at 
1 min ± sD (95% ci)
Mean aPgar at 
5 min ± sD (95% ci)
Pervasive developmental 
disorder, n = 84 (299.xx)
38.73 ± 2.48b (38.19–39.26) 3,368 ± 749c (3,208–3,528) 7.82 ± 1.78d (7.44–8.20) 8.77 ± 0.75e (8.61–8.93)
Cerebral palsy, n = 300 (343.xx) 36.20 ± 2.47 (35.92–36.49) 2,767 ± 735 (2,683–2,850) 6.37 ± 1.73 (6.17–6.57) 7.92 ± 0.74 (7.84–8.00)
Mental retardation, n = 51 (317.
xx or 318.xx or 319.xx)
34.84 ± 2.48 (34.16–35.52) 2,406 ± 733 (2,206–2,608) 6.76 ± 1.75 (6.28–7.24) 8.04 ± 0.73 (7.84–8.24)
95% CI, 95% confidence interval; APGAR, appearance-pulse-grimace-activity-respiration; ICD-9, international classification of disease, 9th revision.
aSubjects examined were continuously HMO-enrolled birth until their initial diagnosis of the outcome examined.
bThere were significantly increased mean gestational ages among subjects diagnosed with a pervasive developmental disorder in comparison to cerebral palsy [t(d) = 8.27, df = 133, 
p < 0.0001] or mental retardation [t(d) = 8.84, df = 106, p < 0.0001] using the t test statistic.
cThere were significantly increased mean birth weights among subjects diagnosed with a pervasive developmental disorder in comparison to cerebral palsy [t(d) = 6.53, df = 131, 
p < 0.0001] or mental retardation [t(d) = 7.33, df = 107, p < 0.0001] using the t test statistic.
dThere were significantly increased mean APGAR scores at 1 min among subjects diagnosed with a pervasive developmental disorder in comparison to cerebral palsy [t(d) = 6.64, 
df = 130, p < 0.0001] or mental retardation [t(d) = 3.39, df = 107, p < 0.005] using the t test statistic.
eThere were significantly increased mean APGAR scores at 5 min among subjects diagnosed with a pervasive developmental disorder in comparison to cerebral palsy [t(d) = 9.21, 
df = 132, p < 0.0001] or mental retardation [t(d) = 5.57, df = 108, p < 0.0001] using the t test statistic.
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Appearance-Pulse-Grimace-Activity-Respiration (APGAR) score 
at 1 and 5 min. In addition, the number of males and females and 
the age of each child’s initial diagnosis were determined for each 
outcome examined.
statistical analyzes
The StatsDirect (version 3.0.150) software was utilized for sta-
tistical analyzes, and a two-sided p-value < 0.05 was considered 
statistically significant. The Fisher’s exact test statistic was utilized 
to compare the male/female ratio among subjects diagnosed with 
a PDD in comparison to subjects diagnosed with CP or MR. 
The t test statistic (assuming unequal variances) was utilized to 
compare the birth demographic parameters of gestational age 
at birth, birth weight, APGAR scores at 1 and 5 min, and mean 
age of the initial diagnosis for each outcome studied. The null 
hypothesis was that for each comparison examined there would 
be no difference among the subjects diagnosed with a PDD in 
comparison to subjects diagnosed with CP or MR.
resUlTs
Overall, the present assessment of the VSD database for children 
without any missing information in their HMO birth file identi-
fied 84 subjects diagnosed with PDD (born between 1995 and 
1999), 300 subjects diagnosed with CP (born between 1995 and 
2000), and 51 subjects diagnosed with MR (born between 1995 
TaBle 1 | a summary of the various types of outcomes examined in the present study.
group examineda (icD-9 code) number of 
males
number of 
females
Male/female 
ratio
Birth years Mean age of initial 
diagnosis ± std (95% ci)
Pervasive developmental disorder, n = 84 (299.xx) 71 13 5.5b 1995–1999 3.13 ± 0.81c (2.96–3.30)
Cerebral palsy, n = 300 (343.xx) 179 121 1.5 1995–2000 1.09 ± 0.81 (1–1.18)
Mental retardation, n = 51 (317.xx or 318.xx or 319.xx) 29 22 1.3 1995–2000 1.62 ± 1.11 (1.31–1.92)
aSubjects examined were continuously HMO-enrolled from birth until their initial diagnosis of the outcome examined.
bThere was a significantly increased male/female ratio among subjects diagnosed with a pervasive developmental disorder in comparison to cerebral palsy (p < 0.0001) or mental 
retardation (p < 0.001) using the Fisher’s exact test statistic.
cThe mean age of initial diagnosis with significantly longer among subjects diagnosed with a pervasive developmental disorder in comparison to cerebral palsy [t(d) = 20.4, df = 133, 
p < 0.0001] or mental retardation [t(d) = 8.4, df = 82, p < 0.0001] using the t test statistic.
and 2000) who were born into the system and continuously 
enrolled until their diagnosis. Table  1 reports the male/female 
distribution, birth years, and mean age of initial diagnoses for 
each of the outcomes examined in this study. Subjects diagnosed 
with a PDD were found to have had a significantly increased 
male/female ratio (male/female ratio =  5.5) in comparison to 
subjects diagnosed with CP (male/female ratio = 1.5, p < 0.0001) 
or MR (male/female ratio = 1.3, p < 0.001). In addition, the mean 
age of initial diagnosis in years for subjects who were diagnosed 
with a PDD was significantly older (3.13 ± 0.81) than the mean 
age of initial diagnosis for subjects who were diagnosed with CP 
(1.09 ± 0.81, p < 0.0001) or MR (1.62 ± 1.11, p < 0.0001).
Table  2 summarizes the results found for the various types 
of birth measurements examined among subjects diagnosed 
with the various outcomes examined in the present study. 
Notably, the mean gestational age in weeks at birth among 
subjects diagnosed with a PDD (38.73 ± 2.48) was significantly 
increased in comparison to the mean gestational age at in weeks 
at birth among subjects diagnosed with CP (36.20  ±  2.47, 
p < 0.0001) or MR (34.84 ± 2.48, p < 0.0001). In addition, the 
mean birth weight in grams among subjects diagnosed with 
a PDD (3,368 ± 749) was significantly greater in comparison 
to subjects diagnosed with CP (2,767 ±  735, p <  0.0001) or 
MR (2,406 ± 733, p < 0.0001). Finally, APGAR scores at 1 and 
5 min among subjects diagnosed with a PDD were significantly 
increased (7.82 ± 1.78 and 8.77 ± 0.75) in comparison to the 
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corresponding APGAR scores for subjects diagnosed with CP 
(6.37 ± 1.73 and 7.92 ± 0.74, p < 0.0001) or MR (6.76 ± 1.75 and 
8.04 ± 0.73 p < 0.0005).
DiscUssiOn
The results of the present hypothesis-testing prospective, longitu-
dinal, case study revealed that the subjects diagnosed by healthcare 
providers with a PDD in comparison to MR or CP within the VSD 
database were different populations. There were highly statistically 
significant differences in the male/female ratio, mean age of initial 
diagnosis, gestational age at birth, mean birth weight, and APGAR 
scores at 1 and 5 min when comparing subjects diagnosed with 
a PDD to those subjects diagnosed with CP or MR. As a conse-
quence, the results observed refute the hypothesis that diagnostic 
substitution can significantly explain the observed increase in 
PDD prevalence in the US during the 1990s.
In comparing our results with previous investigations that 
purportedly suggested diagnostic substitution as a factor con-
tributing to the increasing prevalence of PDD in the US during 
the 1990s, the present study used a much more robust method of 
analysis to confirm that the population of subjects diagnosed with 
a PDD was significantly different than the population of subjects 
diagnosed with CP or MR. This more robust method of analysis 
examined data on specific features which described subjects at 
birth (independent of their eventual diagnosis), and followed 
these children on a continuous, prospective longitudinal basis 
within their respective HMOs until they were diagnosed with the 
outcomes of interest.
By contrast, previous studies purportedly suggesting diagnos-
tic substitution as a factor in or an explanation for increases in 
PDD prevalence have examined only population-based trends 
in diagnoses (i.e., PDD prevalence rates increased as MR preva-
lence rates decreased). For example, investigators conducted 
a population-based study of children born in California from 
1987 to 1994 who had an autism diagnosis (10). Trends in the 
prevalence of a MR diagnosis without an autism diagnosis were 
also investigated to evaluate the role of diagnostic substitution. 
The prevalence of autism increased from 5.8 to 14.9 per 10,000 
subjects, for an absolute change of 9.1 per 10,000 subjects, during 
the study period examined. The prevalence of a MR diagnosis 
without autism decreased from 28.8 to 19.5 per 10,000 subjects, 
for an absolute change of 9.3 per 10,000 subjects, during the same 
period. These investigators concluded that their data suggest that 
the observed increase in autism could be accounted for by the 
change in MR diagnoses.
Similarly, in evaluating the potential for diagnostic substitution 
between PDD and MR diagnoses at the population level, other 
investigators reported that the prevalence of a MR diagnosis in 
special education declined by 2.8 per 1,000 subjects from 1994 
to 2003, whereas autism prevalence increased by 2.6 per 1,000 
subjects (9). These investigators concluded that the total decline 
in MR diagnosis could have offset the total increase in autism 
prevalence to almost 1-for-1.
Investigators also attempted to ascertain whether diagnostic 
substitution was responsible for the increased prevalence of 
autism in the state of California (11). These investigators estimated 
that 26.4% (95% confidence interval  =  16.25–36.48%) of the 
increased autism caseload in California was uniquely associated 
with diagnostic change through a single pathway –  individuals 
previously diagnosed with MR. As a consequence, their estimate 
of diagnostic change could account for no more than a 26.4% 
increase in autism diagnoses.
In addition, another study published in 2009 (15), found that 
diagnostic changes could only partially account for the increases 
in the prevalence of those children receiving an autism diagnosis. 
These investigators found only one-third of the increase in the 
total rate of autism diagnosis could be explained by changes in 
diagnostic criteria, inclusion of milder cases, and earlier age at 
diagnosis.
In a more recent study conducted in California, investigators 
examined key social factors (e.g., diagnostic dynamics, commu-
nity resources, and demographics) that were considered to have 
contributed to increased autism prevalence (16). Even including 
these social factors, the researchers determined that only about 
half of the increase in autism prevalence could be explained. They 
stated that the changing patterns of identification and treatment 
could not completely account for the other percentage increase in 
the prevalence of an autism diagnosis.
All told, the aforementioned studies have significant limita-
tions in their ability to explain the significant increases in the 
prevalence of PDD in the US during the 1990s. For example, some 
of the aforementioned studies attempted to explain increased 
trends in the prevalence of PDD diagnoses by reporting that 
increased trends in the prevalence of PDD diagnoses correlated 
with decreased trends in the prevalence of MR diagnoses. Despite 
attempting to make a connection between these two phenomena, 
the investigators did nothing in their studies to attempt to evaluate 
clinical characteristics such as gender ratio, age of initial diagnosis, 
birth weight, APGAR scores, or gestational age at birth among 
the actual diagnosed subjects to determine, what if any, overlap 
existed in clinical characteristics at the individual level to explain 
the phenomena observed. In addition, some of the aforemen-
tioned studies failed to consider that there are several different 
diagnoses that compose the PDD spectrum, and as a consequence, 
they may have failed to report the true extent of the increase in 
the prevalence of PDD in the US during the 1990s. Another sig-
nificant limitation of some of the aforementioned studies is that 
they examined children born within a limited range for birth years 
(i.e., examining children only born from 1987 to 1994), and as a 
consequence, the studies may not have been able to fully report 
on the increased prevalence of PDD in the US during the 1990s. 
Also, some of the other aforementioned studies reported a limited 
amount of the increases in the rates of autism diagnoses observed 
could be explained by changes in diagnostic criteria, inclusion of 
milder cases, and earlier age at diagnosis. Even when the investiga-
tors in some of the aforementioned studies attempted to evaluate 
the potential impact of key social factors such as diagnostic 
dynamic, community resources, and demographics, these changes 
could only explain a fraction of the increased prevalence of PDD.
Considering the findings reported in the present study, the 
results observed are consistent with the findings of other investi-
gators from the CDC who examined birth weight and gestational 
age characteristics among children diagnosed with autism in 
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comparison to those diagnosed with CP or MR (17). Consistent 
with the results obtained in the present study, those investigators 
observed that the prevalence of children with an autism diagnosis 
in low birth weight or preterm children was markedly lower than 
those diagnosed with MR or CP.
strengths/limitations
An important potential strength of this study was that a ret-
rospective assessment of the VSD database was undertaken to 
evaluate prospectively generated medical records of patients. 
Indeed, all of the subjects examined in this study, were enrolled 
continuously in one of the VSD-participating HMOs from birth 
until their respective diagnoses. As a consequence, factors associ-
ated with enrollment (i.e., adjustment for potential independent 
variables between the different outcomes was not necessary 
because enrollment was from birth to the child’s diagnoses) or 
healthcare-seeking behavior (i.e., adjustment for potential access/
availability of healthcare was continuous for all the outcomes 
examined) were minimized in this study. Further, since, the VSD 
data records analyzed were collected as part of the a subject’s rou-
tine healthcare (i.e., many years before a subject was diagnosed 
with the outcomes under study), it is reasonable to hypothesize 
the healthcare providers were not influenced in reporting the 
various variables examined between subjects diagnosed with a 
PDD in comparison to those diagnosed with MR or CP.
Another potential strength of this study was that consistent 
diagnostic coding was used at the HMOs examined (i.e., ICD-9 
coding was consistently employed). As a consequence, differences 
in diagnostic coding between various healthcare professionals were 
minimized. In addition, since all of the subjects examined in this 
study were born and diagnosed with the various outcomes after 1994, 
all were diagnosed under the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) (18), so that differences in 
the DSM criteria remained consistent for the outcomes examined.
However, there a number of potential limitations to this 
study. Unknown biases, confounders, or statistical chance may 
account for the results observed. These potential limitations seem 
unlikely given the consistent direction, high degree of statistical 
significance, and limited number of statistical tests performed in 
this study. Still, future studies should examine other databases for 
consistency with the observations made in this study.
Another potential limitation of this study is that subjects could 
have received more than one of the outcomes under study, and 
as such, their data would have been included in each of the out-
comes examined. This potential overlap of individuals between 
outcomes examined would bias the results observed toward the 
null hypothesis (i.e., minimizing the differences for the various 
parameters examined between the various outcomes examined), 
but despite this limitation, there were consistent and highly 
significant differences between subjects diagnosed with a PDD 
in comparison to those diagnosed with MR or CP.
Potential additional limitations of this study include that 
some subjects examined by their healthcare providers may not 
have been aware of more subtle neurological dysfunction, some 
subjects may have been misdiagnosed by their healthcare provid-
ers, or some of the variables examined may have been incorrectly 
recorded. A significant impact on the results observed in this 
study should not have occurred from the aforementioned limita-
tions because it is unclear how differential application would have 
occurred to result in the phenomena observed. In addition, it is 
important to realize that data misclassification would tend to bias 
any results toward the null hypothesis.
A still further potential limitation of this study is that subjects 
examined within the VSD database may be different than the gen-
eral US population, and, as a consequence, the findings made may 
not be necessarily generalizable to the general US population. 
This potential limitation was recently investigated by research-
ers who determined that the VSD population is representative 
of the general US population on several key demographic and 
socioeconomic attributes (19). These researchers also reported 
that the VSD population is large enough to ensure an adequate 
representative sample of the general US population.
cOnclUsiOn
The results of the present study revealed that subjects diagnosed by 
healthcare providers with a PDD in comparison to those diagnosed 
with MR or CP, within the VSD database were significantly different 
populations, and, as a result, these differences suggest that diag-
nostic substitution cannot fully explain the increase in diagnosed 
PDD during the 1990s within the US. The observations made in 
the present study call into question the sufficiency of previous 
studies, which have sought to evaluate diagnostic substitution as 
an explanation for the increase in PDD during the 1990s in the 
US by comparing only prevalence changes in diagnosed PDD to 
prevalence changes in diagnosed MR or CP; such an evaluation 
would seem too superficial to yield any valid results without 
additional clinical comparisons of the populations in question. 
The observations made in the present study also provide critical 
insights for healthcare providers attempting to identify important 
and distinguishing clinical features associated with a diagnosis 
of PDD in comparison to a diagnosis of MR or CP. Among the 
important clinical features associated with those diagnosed with a 
PDD observed in the present study were: elevated male/female ratio 
(males significantly more likely than female to be effected); delayed 
mean age of initial diagnosis (mean age of initial diagnosis between 
2 and 4  years-old); and the lack of significant problems at birth 
in comparison to those with a MR or CP diagnosis. By contrast, 
among the important clinical features observed in the present study 
and associated with those diagnosed with MR or CP were: roughly 
equal male/female ratio (males roughly equally likely with female 
to be effected); early mean age of initial diagnosis (mean age of 
initial diagnosis within the first 2 years of life); and with significant 
problems at birth in comparison to those with a PDD diagnosis.
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